MorphoSys AG (Xetra:MOR; Pink:MPSYF) is taking a page out of the playbook of Celgene Corp. (NASDAQ:CELG) by making a strategic investment in an early stage biotech.

Last month, MorphoSys participated in the €4.8 million ($6.2 million) series A round for Dutch peptide company Lanthio Pharma B.V. The round was co-led by existing investor BioGeneration Ventures